ArticleCancer management and research2018
Altered epidermal fatty acid-binding protein expression in hepatocellular carcinoma predicts unfavorable outcomes.
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Unveiling Metabolic Signatures as Potential Biomarkers in Common Cancers: Insights from Lung, Breast, Colorectal, Liver, and Gastric Tumours.Biomolecules · 2025Review
- Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients.Scientific reports · 2024Article
- Health-Related Quality of Life in Patients with Chronic Hepatitis B: A Meta-Analysis of Observational Studies.Iranian journal of public health · 2023Review
- Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma.The Journal of international medical research · 2020Article
- Adrenomedullin inhibits tumor metastasis and is associated with good prognosis in triple-negative breast cancer patients.American journal of translational research · 2020Article
- Decreased expression levels of ELOVL6 indicate poor prognosis in hepatocellular carcinoma.Oncology letters · 2019Article
- Risk factors associated with fatigue in chronic hepatitis B patients.Patient preference and adherence · 2019Article
- Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma.Infectious agents and cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHepatocellular carcinoma (HCC) is a rapidly proliferating malignancy that requires large amounts of fatty acids to synthesize cellular membranes and provide energy. Epidermal fatty acid-binding protein (EFABP) is uniquely expressed in epidermal cells, but its role and expression in HCC are not clear. SUBJECTS AND
methodsA total of 804 HCC specimens were collected to construct a tissue microarray (TMA) and for immunohistochemistry (IHC) analysis. The relationship between EFABP expression and clinical features of patients with HCC was analyzed.
resultsThe EFABP IHC score for HCC tissue was 0.76±0.69, being significantly higher than that for matched nontumorous tissue (0.48±0.55;
conclusionOur data revealed that EFABP expression was increased in HCC samples. High EFABP expression was correlated with shorter survival times in patients with HCC and served as an independent factor for worse outcomes. Our study therefore provides a promising bio-marker for the prognostic prediction of HCC and a potential therapeutic target for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.